Slow coronary flow. Other forms of angina pectoris
Conditions
Interventions
Intervention 1: Intervention group: In this group, Mebourein oral tablet with a dose of 200 mg every 12 hours will be given to patients in the intervention group in the form of one tablet for one mon
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Performing diagnostic angiography due to chronic symptoms or positive non-invasive test TIMI frame count greater than 27 in angiography In the injection of angiography contrast material, after 3 heartbeats, the contrast material has not reached the end of the coronary arteries in patients.
Exclusion criteria
Exclusion criteria: Non-satisfaction or non-cooperation in taking Mebourein or placebo Failure to visit the heart clinic regularly within 1 month of angiography History of heart failure in echocardiography Any patient who has a history of valvular disease or any other heart disease Patients who experience acute coronary events during this period Patients with vascular ectasia Involvement of more than 50% of epicardial vessels
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms of patients including chest pain, functional chest pain and functional shortness of breath. Timepoint: One month after the first visit and drug consumption. Method of measurement: Evaluation and questioning of patients by a specialist doctor and registration in the checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNazanin Karimi
Tehran University of Medical Sciences
Outcome results
None listed